Dr. Friederike Holze — Clinical Pharmacology of Classical Psychedelics

Value of the Information & Strength of the Argument

The talk provides high-value information, presenting original data from the speaker’s own clinical trials, which are rare and valuable in this field. The argumentation is solid, systematically comparing compounds, doses, and effects, and linking pharmacokinetics to pharmacodynamics. The speaker is careful to distinguish between observed effects and interpretations, and acknowledges limitations such as small sample sizes and the need for replication. The use of visual data (graphs) strengthens the presentation, and the speaker’s expertise is evident.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high: the speaker references her own peer-reviewed publications and mentions FDA guidance, indicating alignment with regulatory standards. The sources are credible (University Hospital Basel, peer-reviewed journals). The title accurately reflects the content, which is a focused lecture on clinical pharmacology. The talk is well-structured and evidence-based, with clear explanations of complex concepts.

The title accurately reflects the content: a focused talk on the clinical pharmacology of classical psychedelics, covering pharmacokinetics, pharmacodynamics, interactions, and therapeutic implications.

9/10

Presentation by a leading clinical researcher at University Hospital Basel, drawing on her own Phase I/II studies and peer-reviewed publications. The talk is technically detailed, transparent about limitations, and aligns with current scientific consensus.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to classical psychedelics and their definition as 5-HT2A agonists.
• 05:00Comparison of LSD and psilocybin: subjective effects, duration, and cardiovascular effects.
• 10:00Discussion of pharmacokinetics: half-lives, variability, and dose equivalents.
• 15:00DMT IV infusion studies: plateau effect, individual differences, and self-titration.
• 20:00Pharmacokinetic interactions: CYP2D6 metabolism and MDMA co-administration.
• 25:00Pharmacodynamic interactions: SSRIs and their effects on psychedelic experience.
• 30:00Therapeutic markers: correlation of acute positive effects with long-term outcomes.
• 35:00Dose-response study for LSD: ceiling effects and implications for dosing.
• 40:00Case reports on patients without acute experiences and their outcomes.
• 45:00Safety considerations and use of ketanserin as an antidote.

• Editorial on clinical pharmacology of psychedelics — Mentioned as an editorial accompanying a pharmacokinetics paper.
• FDA draft guidance on psychedelic drug development — Referenced as a regulatory document emphasizing the need for pharmacokinetic and pharmacodynamic characterization.

• Holze et al. (2020) - Dose-response relationships of LSD and psilocybin — The speaker's own study comparing LSD and psilocybin, likely published in a peer-reviewed journal.
• Holze et al. (2021) - Pharmacokinetics of LSD and psilocybin — The speaker's pharmacokinetics paper, which received an editorial.

• Anecdotal reports of higher LSD doses — The speaker notes that some individuals report stronger effects at higher doses than the ceiling observed in her studies, suggesting potential differences between controlled and uncontrolled settings.